August 26, 2024 11:36 AM EDT

Another major PBM will cut AbbVie's Humira from its largest commercial formularies

Shelby Livingston

Senior health tech reporter

Cigna’s pharmacy benefit manager Express Scripts said it will remove Humira from its largest commercial drug formularies in 2025 to make way for its biosimilars …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Another major PBM will cut AbbVie's Humira from its largest commercial formularies

Shelby Livingston

Senior health tech reporter

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Outlook's shares crash as wet AMD drug flunks Phase 3 test

An­oth­er ma­jor PBM will cut Ab­b­Vie's Hu­mi­ra from its largest com­mer­cial for­mu­la­ries

Shelby Livingston

Senior health tech reporter

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Another major PBM will cut AbbVie's Humira from its largest commercial formularies

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Outlook's shares crash as wet AMD drug flunks Phase 3 test